Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment

References

• Al-Kassas RS, Al-Gohary O, Al-Faadhel MM. Controlling of systemic absorption of gliclazide through incorporation into alginate beads. Int J Pharm, 2007;341(1):230–7
   PubMed Web of Science ®Google Scholar
• Al-Salami H, Butt G, Fawcett JP, Tucker IG, Golocorbin-Kon S, Mikov M. Probiotic treatment reduces blood glucose levels and increases systemic absorption of gliclazide in diabetic rats. Eur J Drug Metab Pharmacokinet, 2008a;33(2):101–6
   Google Scholar
• Al-Salami H, Butt G, Tucker I, Mikov M. Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics. Methods Find Exp Clin Pharmacol, 2008b;30(2):107–13
   Google Scholar
• AI-Salami H, Butt G, Tucker I, Mikov M. The influence of probiotic pretreatment on the ilealpermeation of gliclazide in healthy and diabetic rats. Arch Drug lnf 2008c;1(1):35–41
   Google Scholar
• Al-Salami H, Butt G, Tucker I, Mikov M. Influence of the semisynthetic bile acid (MKC) on the ileal permeation of gliclazide in healthy and diabetic rats. Pharm Rep, 2008d;60(4):532–41
   Google Scholar
• Al-Salami H, Butt G, Tucker I, Skrbic R, Golocorbin-Kon S, Mikov M. Probiotic pre-treatment reduces gliclazide permeation (ex vivo) in healthy rats but increases it in diabetic rats to the level seen in untreated healthy rats. Arch Drug Inf, 2008e;1:35–41
   Google Scholar
• Al-Salami H, Butt G, Tucker I, Fawcett PJ, Golocorbin-Kon S, Mikov I, Mikov M. Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats. Eur J Drug Metab Pharmacokinet, 2009;34:43–50
   Google Scholar
• AI-Salami H. Butt G,Tucker I, Golocorbin-Kon S, Mikov M. Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats. Eur J Drug Metab Pharmacokinet, 2012;37(2):99–108
   Google Scholar
• Anal AK, Bhopatkar D, Tokura S, Tamura H, Stevens WF. Chitosan-alginate multilayer beads for gastric passage and controlled intestinal release of protein. Drug Dev Ind Pharm, 2003;29(6):713–24
   Google Scholar
• Anal AK, Stevens WF. Chitosan-alginate multilayer beads for controlled release of ampicillin. Int J Pharm, 2005;290(1):45–54
   PubMedGoogle Scholar
• Bajpai J, Bajpai A, Mishra A. Dynamics of controlled release of potassium nitrate from a highly swelling binary biopolymeric blend of alginate and pectin. J Macromol Sci A Pure Appl Chem, 2006;43(1):165–86
   Web of Science ®Google Scholar
• Bakatselou V, Oppenheim RC, Dressman JB. Solubilization and wetting effects of bile salts on the dissolution of steroids. Pharm Res, 1991;8(12):1461–9
   PubMed Web of Science ®Google Scholar
• Barakat NS, Shazly GA, Almedany AH. Influence of polymer blends on the characterization of gliclazide–encapsulated into poly (epsilon-caprolactone) microparticles. Drug Dev Ind Pharm, 2013;39(2):352–62
   PubMed Web of Science ®Google Scholar
• Barbeau WE, Bassaganya-Riera J, Hontecillas R. Putting the pieces of the puzzle together – A series of hypotheses on the etiology and pathogenesis of type 1 diabetes. Med Hypotheses, 2007;68(3):607–19
   PubMed Web of Science ®Google Scholar
• Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia, 2007;50(11):2374–83
   Google Scholar
• Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, Hu FB. Diabetes in Asia: Epidemiology, risk factors, and pathophysiology. JAMA, 2009;301(20):2129–40
   Google Scholar
• Fakhoury M, Coussa-Charley M, Al-Salami H, Kahouli I, Prakash S. Use of artificial cell microcapsule containing thalidomide for treating TNBS-induced Crohn's disease in mice. Curr Drug Deliv, 2014;11(1):146–53
   Google Scholar
• Jyothi NV, Prasanna PM, Sakarkar SN, Prabha KS, Ramaiah PS, Srawan GY. Microencapsulation techniques, factors influencing encapsulation efficiency. J Microencapsul, 2010;27(3):187–97
   Google Scholar
• Lalic-Popovic M, Vasovic V, Milijasevic B, Golocorbin-Kon S, Al-Salami H, Mikov M. Deoxycholic Acid as a modifier of the permeation of gliclazide through the blood brain barrier of a rat. J Diabet Res, 2013;1–8:598603
   Google Scholar
• Luner PE. Wetting properties of bile salt solutions and dissolution media. J Pharm Sci, 2000;89(3):382–95
   PubMed Web of Science ®Google Scholar
• Martoni C, Bhathena J, Urbanska AM, Prakash S. Microencapsulated bile salt hydrolase producing Lactobacillus reuteri for oral targeted delivery in the gastrointestinal tract. Appl Microbiol Biotechnol, 2008;81(2):225–33
   Google Scholar
• Mikov M, Boni NS, Al-Salami H, Kuhajda K, Kevresan S, Golocorbin-Kon S, et al. Bioavailability and hypoglycemic activity of the semisynthetic bile acid salt, sodium 3alpha,7alpha-dihydroxy-12-oxo-5beta-cholanate, in healthy and diabetic rats. Eur J Drug Metab Pharmacokinet, 2007;32(1):7–12
   Google Scholar
• Mikov M, Al-Salami H, Golocorbin-Kon S, Skrbic R, Raskovic A, Fawcett JP. The influence of 3alpha,7alpha-dihydroxy-12-keto-5beta-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes. Eur J Drug Metab Pharmacokinet, 2008;33(3):137–42
   Google Scholar
• Mooranian A, Negrulj R, Mathavan S, Martinez J, Sciarretta J, Chen-Tan N, Mukkur TK, Mikov M, Lalic-Popovic M, Stojančević M, et al. A complex microencapsulated system: A platform for optimised oral delivery of antidiabetic drug-bile acid formulations. Pharma Dev Tech, 2014 (In press)
   Google Scholar
• Mooranian A, Negrulj R, Mathavan S, Martinez J, Sciarretta J, Chen-Tan N, Mukkur TK, Mikov M, Lalic-Popovic M, Stojančević M, et al. Stability and release kinetics of an advanced gliclazide-cholic acid formulation: The use of artificial-cell microencapsulation in slow release targeted oral delivery of antidiabetics. J Pharm Innovation, in press
   Google Scholar
• Moore PA, Zgibor JC, Dasanayake AP. Diabetes: A growing epidemic of all ages. J Am Dent Assoc, 2003;134:11S–15S
   PubMedGoogle Scholar
• Negrulj R, Mooranian A, Al-Salami H. Potentials and limitations of bile acids in type 2 diabetes mellitus: Applications of microencapsulation as a novel oral delivery system. J Endocrinol Diabetes Mellitus, 2013;1(2):49–59
   Google Scholar
• Nochos A, Douroumis D, Bouropoulos N. In vitro release of bovine serum albumin from alginate/HPMC hydrogel beads. Carbohydr Polym, 2008;74(3):451–7
   Web of Science ®Google Scholar
• Pasparakis G, Bouropoulos N. Swelling studies and in vitro release of verapamil from calcium alginate and calcium alginate-chitosan beads. Int J Pharm, 2006;323(1):34–42
   PubMed Web of Science ®Google Scholar
• Pavlovic N, Stankov K, Mikov M. Probiotics-interactions with bile acids and impact on cholesterol metabolism. Appl Biochem Biotechnol, 2012;168(7):1880–95
   PubMed Web of Science ®Google Scholar
• Prajapati SK, Tripathi P, Ubaidulla U, Anand V. Design and development of gliclazide mucoadhesive microcapsules: In vitro and in vivo evaluation. AAPS PharmSciTech, 2008;9(1):224–30
   Google Scholar
• Raskovic A, Mikov M, Skrbic R, Jakovljevic V, Vasovic V, Posa M, et al. Effect of stevioside and sodium salt of monoketocholic acid on glycemia in normoglycemic and diabetic rats. Eur J Drug Metab Pharmacokinet, 2008;33(1):17–22
   Google Scholar
• Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs, 2004;64(12):1339–58
   PubMed Web of Science ®Google Scholar
• Takka S, Acarturk F. Calcium alginate microparticles for oral administration: I: Effect of sodium alginate type on drug release and drug entrapment efficiency. J Microencapsul, 1999;16(3):275–90
   PubMed Web of Science ®Google Scholar
• Takka S, Cali AG. Bile salt-reinforced alginate-chitosan beads. Pharm Dev Technol, 2012;17(1):23–9
   PubMed Web of Science ®Google Scholar
• Wee S, Gombotz WR. Protein release from alginate matrices. Adv Drug Deliv Rev, 1998;31(3):267–85
   PubMed Web of Science ®Google Scholar
• Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care, 2004;27(5):1047–53
   Google Scholar
• Yang L, Zhang H, Mikov M, Tucker IG. Physicochemical and biological characterization of monoketocholic acid, a novel permeability enhancer. Mol Pharm, 2009;6(2):448–56
   Google Scholar